Abstract

BackgroundChronic nasal carriage of Staphylococcus aureus (SA) has been shown to increase the risk of relapse in patients with Granulomatosis with polyangiitis (GPA). B cell depletion with Rituximab (RTX) is...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis.
Johannes C Nossent ... Emilio Besada
PeerJ | VOL. 3
Johannes C Nossent, et. al.Johannes C Nossent ... Emilio Besada
25 Jun 2015
No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses.
Xavier Puéchal ... Christine Vinter
Rheumatology (Oxford, England) | VOL. 59
Xavier Puéchal, et. al.Xavier Puéchal ... Christine Vinter
24 Jun 2019
Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
Ken-Ei Sada ... Takao Fujii
Arthritis research & therapy | VOL. 17
Ken-Ei Sada, et. al.Ken-Ei Sada ... Takao Fujii
02 Nov 2015
Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).
Charles D Pusey ... Scott R Henderson
Medicine | VOL. 93
Charles D Pusey, et. al.Charles D Pusey ... Scott R Henderson
01 Dec 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers